Fabric Genomics focuses on genomic analysis and reporting, using artificial intelligence to provide clinical insights for hospitals and diagnostic labs. Their main product, Fabric Enterprise, analyzes Next-Generation Sequencing (NGS) data to identify genetic variants linked to diseases, supporting various genomic tests. The company operates on a software-as-a-service (SaaS) model, allowing clients to quickly interpret genomic data, which is essential for diagnosing critical conditions. Fabric Genomics aims to improve the speed and accuracy of genetic testing, enhancing patient outcomes and reducing healthcare costs.

Bay City Capital

Casdin Capital

Artis Ventures

Acadia Woods Partners

Roche Venture Fund

LDV Partners

Ping An Ventures

LDV Capital

Enterprise Software

AI & Machine Learning

Healthcare

Fabric Genomics

OAKLAND, Calif. SALT LAKE CITY--(BUSINESS WIRE)--Fabric Genomics, the leader in artificial intelligence (AI)-powered next generation sequencing interpretation, is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases. This collaboration is a milestone in helping children facing critical health challenges and receiving care in inpatient and outpatient care settings, starting at Intermountain Primary Children’s Hospital in Salt Lake City, a renowned leader in pediatric healthcare and the flagship pediatric hospital for Intermountain Health. The sample-to-report genome service enables healthcare professionals to identify genetic disorders with unprecedented speed and precision and to tailor treatment plans to the unique genetic makeup of each infant. Offered by partners Broad Clinical Labs and Fabric Genomics, the sample-to-report genomic analysis service makes whole genome sequencing (WGS) and diagnosis accessible to healthcare systems who may not currently have genomics infrastructure and expertise in-house

Fabric Genomics Partners With Intermountain Children’S Health To Enhance Precision Diagnosis Of Infants And Children Using Whole Genome Sequencing From Broad Clinical Labs

ATHENS, Greece & OAKLAND, Calif.--(BUSINESS WIRE)--#AI--PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps, a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece. Fabric AI technology for interpretation of the human genome, powered by the Fabric GEM AI algorithm, will be adapted into the FirstSteps clinical support tool, empowering clinicians to provide timely medical intervention for patients with rare genetic diseases in Greece.“The introduction of the Fabric AI platform into the national population health initiative FirstSteps represents an extension of a longstanding partnership between the two companies, and it will help create an ecosystem to enable drug discovery and development for rare diseases,” said Petros Tsipouras, MD, Managing Partner of PlumCare RWE and Scientific Director of FirstSteps.Professor Dimitris Thanos, PhD, Member of the Academy of Athens and Vice Chairman of the Scientific Advisory Board of FirstSteps said, “Bringing the Fabric AI platform to support and speed up our variant interpretation process will enhance the overall performance of the FirstSteps program and help improve the lives of patients with rare genetic diseases in Greece and around the world.”“We are excited to extend our partnership with PlumCare RWE into the new FirstSteps program to bring our genomics AI analysis technology to Greece to support their precision medicine initiative and additionally, to foster an innovation hub in Greece. This partnership will enable us to expand our reach to Europe and improve outcomes for patients,” said Martin Reese, PhD, Co-Founder and CEO of Fabric Genomics.Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program. This partnership comes on the heels of Fabric Genomics’ previously announced successful partnerships with Rady Children’s Institute for Genomic Medicine and with the Broad Institute of MIT and Harvard offering affordable clinical whole genome analysis in its effort to bring better genomics-based healthcare to all patients.About PlumCare RWEPlumCare RWE is at the forefront of biotechnology and healthcare data, harnessing the power of real-world evidence and multi-omics analysis to provide actionable insights that enhance both population health and individual family well-being. Our commitment to precision medicine is evident through our comprehensive services that include early screening, accurate diagnosis, and timely interventions, all aimed at fostering better health outcomes for families

Plumcare And Fabric Genomics Announce A Strategic Partnership To Integrate The Fabric Ai Platform With Plumcare'S Firststeps(Tm) Newborn Genome Screening Program In Greece

Illumina partners with Veracyte; Boston Scientific Corporation acquires Relievant Medsystems; Oxford Nanopore collaborates with Fabric Genomics.

Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

Project FIND-OUT facilitates early genetic diagnosis in infants 3 – 12 months of age with symptoms of genetic neurodevelopmental disordersBRENTWOOD, Tenn., Nov. 8, 2023 /PRNewswire/ -- COMBINEDBrain, a non-profit organization dedicated to fast-tracking cures for neurodevelopmental disorders, today announced the launch of Project FIND-OUT (Fast Infant Neurodevelopmental Diagnosis via Outpatient Testing), a collaboration among leading non-profit, academic, and industry organizations.Project FIND-OUT provides whole genome sequencing (WGS) to infants who have early symptoms of rare genetic neurodevelopmental disorders. The goals of the study are to expedite diagnosis of rare genetic neurodevelopmental disorders, to generate evidence on the benefits of genetic testing for patients and their families, and to build capacity at a local level for implementation of genetic testing programs. "Curtailing the diagnostic odyssey through broad genetic testing at first signs of symptoms promises to transform the diagnosis and management of children with neurodevelopmental disorders over the next few years," stated Dr. Seth Berger, M.D., Ph.D., a pediatric geneticist at Children's National Hospital. Dr

Combinedbrain Announces The Launch Of Project Find-Out

At ASHG, Fabric Genomics announces software deals with Oxford Nanopore, DNAnexus.

At ASHG, Fabric Genomics Announces Software Deals with Oxford Nanopore, DNAnexus

Through the partnership, Fabric Genomics will integrate its advanced genomic analysis tools and AI engine with the DNAnexus Precision Health Cloud, providing users with a push-button solution to move quickly from sample to evidence-backed analysis to actionable clinical reports.

Fabric Genomics and DNAnexus Team Up to Improve Scale and Speed of Data Analysis for Genomic Medicine

Oxford Nanopore Technologies plc (Oxford Nanopore), the nanopore-sequencing company delivering unparalleled rich genomic data insights, and Fabric Genomics, the leading AI-driven analysis and interpretation software provider, today announced a new collaboration to develop a scalable software solution for the end-to-end analysis and clinical reporting of rich genomic data.

Oxford Nanopore Technologies and Fabric Genomics collaborate to launch an integrated whole-genome sequencing solution to advance the future of paediatric patient care

In June 2023, Oxford Nanopore partnered with Genetex for the development of a software solution for end-to-end analysis and clinical reporting of nanopore sequencing data.

Oxford Nanopore and Fabric Genomics launch software for paediatric patient care

➤ In 2020, Fabric Genomics, a global leader in clinical genomic data interpretation, announced the release of Fabric GEM, a novel algorithm that quickly and efficiently identifies the likely genetic cause of rare diseases from next-generation sequencing data, allowing for faster diagnosis and potentially more effective treatment.

Unparalleled Research on Precision Medicine Software Market With Current and Future Growth Analysis by Forecast From 2023 to 2029 | 2bPrecise LLC, Syapse Inc., PierianDx Inc., Fabric Genomics, SOPHiA GENETICS SA, N-of-One Inc.

Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director. An experienced diagnostics leader and board-certified clinical geneticist, Dr. Hofherr brings more than a decade of experience in execution and innovation in large-scale clinical genomics programs in academia and industry to Fabric Genomics. (Photo: Business Wire). Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director. An experienced diagnostics leader and board-certified clinical geneticist, Dr. Hofherr brings more than a decade of experience in execution and innovation in large-scale clinical genomics programs in academia and industry to Fabric Genomics. (Photo: Business Wire)

Fabric Genomics Expands Leadership Team In Precision Medicine

AI-driven genomic analysis for healthcare

Fabric Genomics

AI-driven genomic analysis for healthcare

Fabric Genomics

AI-driven genomic analysis for healthcare

About

Simplify's Take

What believers are saying

What critics are saying

What makes Fabric Genomics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

There are no jobs for Fabric Genomics right now.